Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

Summary

This phase I study will involve escalating doses of CAMPATH until the goal dose for the cohort is tolerated. The CAMPATH goal dose will be administered to the patient subcutaneously (SQ) 3 times per week for up to 12 weeks.

Timeline

Start

2003-12

Primary completion

—

Completion

2005-09

Drugs

Indications